Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 3,953,200 | 2,762,100 | 1,679,200 | 646,300 | -535,600 |
| Depreciation Amortization | 209,800 | 154,100 | 100,100 | 48,400 | 207,200 |
| Income taxes - deferred | -510,800 | -541,300 | -305,400 | -191,600 | -348,800 |
| Accounts receivable | -347,300 | -247,900 | -188,000 | -169,600 | -99,300 |
| Accounts payable and accrued liabilities | 36,800 | -1,500 | 33,800 | 26,200 | 49,500 |
| Other Working Capital | -1,199,100 | -251,300 | -400,900 | -268,500 | -514,800 |
| Other Operating Activity | 1,488,800 | 1,259,200 | 973,200 | 727,700 | 749,200 |
| Operating Cash Flow | $3,631,400 | $3,133,400 | $1,892,000 | $818,900 | $-492,600 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -437,600 | -288,200 | -186,400 | -40,700 | -297,700 |
| Purchase Of Investment | -6,396,500 | -5,165,900 | -3,820,600 | -1,647,400 | -7,438,200 |
| Sale Of Investment | 5,913,400 | 4,805,600 | 3,476,300 | 1,637,600 | 4,465,600 |
| Purchase Sale Intangibles | N/A | 0 | 0 | 0 | -187,700 |
| Other Investing Activity | -24,700 | -8,800 | -9,600 | -5,300 | -499,700 |
| Investing Cash Flow | $-945,400 | $-657,300 | $-540,300 | $-55,800 | $-3,770,000 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -5,400 | -4,000 | -2,600 | -1,300 | -33,600 |
| Common Stock Issued | 127,700 | 73,700 | 65,800 | 16,700 | 114,600 |
| Common Stock Repurchased | -2,017,400 | -1,889,000 | -817,900 | -426,100 | -1,177,100 |
| Other Financing Activity | -366,200 | -364,800 | -274,900 | -269,700 | -398,800 |
| Financing Cash Flow | $-2,261,300 | $-2,184,100 | $-1,029,600 | $-680,400 | $-1,494,900 |
| Exchange Rate Effect | 90,900 | 83,600 | 87,700 | 30,500 | -42,600 |
| Beginning Cash Position | 4,572,200 | 4,572,200 | 4,572,200 | 4,572,200 | 10,372,300 |
| End Cash Position | 5,087,800 | 4,947,800 | 4,982,000 | 4,685,400 | 4,572,200 |
| Net Cash Flow | $515,600 | $375,600 | $409,800 | $113,200 | $-5,800,100 |
| Free Cash Flow | |||||
| Operating Cash Flow | 3,631,400 | 3,133,400 | 1,892,000 | 818,900 | -492,600 |
| Capital Expenditure | -437,600 | -288,200 | -186,400 | -40,700 | -297,700 |
| Free Cash Flow | 3,193,800 | 2,845,200 | 1,705,600 | 778,200 | -790,300 |